Ublituximab: Difference between revisions
Content deleted Content added
templated cite |
m Added UNII |
||
Line 30: | Line 30: | ||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = none |
| ChemSpiderID = none |
||
⚫ | |||
| CAS_number = 1174014-05-1 |
| CAS_number = 1174014-05-1 |
||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = U59UGK3IPC |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
Revision as of 16:12, 25 January 2021
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in "U2" Phase 3 clinical trials for chronic lymphocytic leukemia in combination with Umbralisib.
See also
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ Clinical trial number NCT03277261 for "A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)" at ClinicalTrials.gov